1. Home
  2. ELDN vs WIA Comparison

ELDN vs WIA Comparison

Compare ELDN & WIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

HOLD

Current Price

$3.10

Market Cap

235.1M

Sector

Health Care

ML Signal

HOLD

Logo Western Asset Inflation-Linked Income Fund

WIA

Western Asset Inflation-Linked Income Fund

HOLD

Current Price

$8.14

Market Cap

188.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELDN
WIA
Founded
2004
2003
Country
United States
United States
Employees
33
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
235.1M
188.7M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
ELDN
WIA
Price
$3.10
$8.14
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
1.3M
36.9K
Earning Date
05-13-2026
01-01-0001
Dividend Yield
N/A
12.29%
EPS Growth
30.67
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.35
$7.95
52 Week High
$4.60
$8.54

Technical Indicators

Market Signals
Indicator
ELDN
WIA
Relative Strength Index (RSI) 59.62 53.59
Support Level $2.45 $8.10
Resistance Level $3.17 $8.31
Average True Range (ATR) 0.20 0.05
MACD -0.01 0.02
Stochastic Oscillator 70.00 94.35

Price Performance

Historical Comparison
ELDN
WIA

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

About WIA Western Asset Inflation-Linked Income Fund

Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.

Share on Social Networks: